AU2022205969A1 - Use of a kras g12c inhibitor in treating cancers - Google Patents

Use of a kras g12c inhibitor in treating cancers Download PDF

Info

Publication number
AU2022205969A1
AU2022205969A1 AU2022205969A AU2022205969A AU2022205969A1 AU 2022205969 A1 AU2022205969 A1 AU 2022205969A1 AU 2022205969 A AU2022205969 A AU 2022205969A AU 2022205969 A AU2022205969 A AU 2022205969A AU 2022205969 A1 AU2022205969 A1 AU 2022205969A1
Authority
AU
Australia
Prior art keywords
subject
mutation
kras
positive
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022205969A
Other languages
English (en)
Other versions
AU2022205969A9 (en
Inventor
Agnes L. ANG
Haby HENARY
Gataree Ngarmchamnanrith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2022205969A1 publication Critical patent/AU2022205969A1/en
Publication of AU2022205969A9 publication Critical patent/AU2022205969A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2022205969A 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers Pending AU2022205969A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17
PCT/US2022/011673 WO2022150628A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Publications (2)

Publication Number Publication Date
AU2022205969A1 true AU2022205969A1 (en) 2023-07-06
AU2022205969A9 AU2022205969A9 (en) 2024-02-08

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205969A Pending AU2022205969A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Country Status (8)

Country Link
US (1) US20240091230A1 (https=)
EP (2) EP4650006A3 (https=)
JP (1) JP2024502446A (https=)
AU (1) AU2022205969A1 (https=)
CA (1) CA3206523A1 (https=)
MX (1) MX2023007918A (https=)
TW (1) TWI906448B (https=)
WO (1) WO2022150628A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Also Published As

Publication number Publication date
EP4650006A3 (en) 2026-01-14
US20240091230A1 (en) 2024-03-21
EP4650006A2 (en) 2025-11-19
TW202241442A (zh) 2022-11-01
WO2022150628A1 (en) 2022-07-14
EP4274579A1 (en) 2023-11-15
TWI906448B (zh) 2025-12-01
MX2023007918A (es) 2023-07-13
CA3206523A1 (en) 2022-07-14
AU2022205969A9 (en) 2024-02-08
JP2024502446A (ja) 2024-01-19

Similar Documents

Publication Publication Date Title
US20240091230A1 (en) Use of kras g12c inhibitor in treating cancers
Ma et al. A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer
US20250375452A1 (en) Sotorasib dosing regimen
KR20210064252A (ko) Cdc7 억제제를 포함하는 암의 치료 방법
JP2024510612A (ja) ソトラシブ投与レジメン
US20260069593A1 (en) Methods for treating cancer
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
Johnson et al. 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
EP4694891A1 (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
HK40126893A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
Burns et al. MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
JP2026513999A (ja) 癌治療におけるソトラシブ／カルボプラチン／ペメトレキセドについての投与計画
WO2024015360A1 (en) Methods of treating cancer
Langer Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
HK40102675A (zh) 索托拉西布给药方案

Legal Events

Date Code Title Description
SREP Specification republished